Dossier
vaccine makers
Coverage of vaccine makers in the Nexus archive.
- STAT+: Facing a brutal run, battered vaccine makers still see cause for hope
Vaccine makers are navigating significant challenges, including canceled mRNA vaccine contracts and reduced government funding, but some remain cautiously optimistic. The article highlights disruptions caused by Health Secretary Robert F. Kennedy Jr.'s actions, such as dismantling universal vaccine recommendations and potential future policy shifts.
- Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know
Eli Lilly announced it will acquire three privately held vaccine makers in deals totaling nearly $4 billion, signaling a significant expansion into the vaccine sector.